Rheonix Inc - Product Pipeline Analysis, 2018 Update
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Rheonix Inc Company Overview 5
Rheonix Inc Company Snapshot 5
Rheonix Inc Pipeline Products and Ongoing Clinical Trials Overview 5
Rheonix Inc – Pipeline Analysis Overview 8
Rheonix Inc - Key Facts 8
Rheonix Inc - Major Products and Services 9
Rheonix Inc Pipeline Products by Development Stage 10
Rheonix Inc Pipeline Products Overview 12
Clopidogrel PGx Assay 12
Clopidogrel PGx Assay Product Overview 12
EncompassMDx Platform 13
EncompassMDx Platform Product Overview 13
GI CARD Assay 14
GI CARD Assay Product Overview 14
KRAS CARD Assay 15
KRAS CARD Assay Product Overview 15
Rheonix CARD - HIV Assay 16
Rheonix CARD - HIV Assay Product Overview 16
Rheonix CARD - Zika Virus Assay 17
Rheonix CARD - Zika Virus Assay Product Overview 17
Rheonix CARD HPV Assay 18
Rheonix CARD HPV Assay Product Overview 18
Rheonix CARD System 19
Rheonix CARD System Product Overview 19
Rheonix SeptiCARD Device 20
Rheonix SeptiCARD Device Product Overview 20
Rheonix STI(s) CARD Assay 21
Rheonix STI(s) CARD Assay Product Overview 21
UTI CARD Assay 22
UTI CARD Assay Product Overview 22
Warfarin PGx Assay 23
Warfarin PGx Assay Product Overview 23
Rheonix Inc - Key Competitors 24
Rheonix Inc - Key Employees 25
Rheonix Inc - Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Rheonix Inc, Recent Developments 27
Feb 22, 2018: NYU Researchers Adapt HIV Test in Developing Rapid Diagnostic Test for Zika Virus 27
Apr 19, 2016: Rheonix To Pursue Rapid Zika Virus Diagnostic 28
Mar 10, 2016: Rheonix Develops Fully Automated Microfluidic System that Improves HIV Testing 29
Feb 10, 2015: Rheonix Receives $1.5 Million SBIR Phase II Grant from the National Institute of Dental & Craniofacial Research of the National Institutes of Health 29
Feb 10, 2015: Rheonix Receives $1.5 Million SBIR Phase II Grant from the National Institute of Dental and Craniofacial Research of the National Institutes of Health to Complete Development of a Rapid Point-of-Care Test for HIV/AIDS 30
Mar 24, 2014: Rheonix Invited to Present at 'The Future of In-Vitro Diagnostics' Conference hosted by Siemens 31
Jun 14, 2012: Rheonix Highlights First Fully Automated FFPE KRAS-Biomarker Assay At BIO International Convention 31
Dec 15, 2011: Rheonix Announces Novel Microarray Production Technology To Support Multiplexed Endpoint Detection Of SNPs On Rheonix CARD System 32
Nov 16, 2011: Rheonix Appoints Vice President Of Operations And Quality Manager 32
Jul 27, 2011: Rheonix Announces Positive Results Of New SeptiCARD For Detection Of Septicemia 32
Appendix 34
Methodology 34
About GlobalData 37
Contact Us 37
Disclaimer 37
Summary
Rheonix Inc (Rheonix) is a medical equipment company that develops molecular diagnostic products. The company offers automated and integrated molecular testing device. It develops Rheonix CARD cartridge technology which penetrates molecular testing markets from diagnostics labs to applied markets testing for food and beverage applications and next-generation sequencing sample preparation. Rheonix also develops Encompass workstation products such as Encompass MDx and Encompass Optimum. The company’s Encompass Optimum workstation provides information per sample for food and beverage testing. Rheonix is headquartered in Ithaca, New York, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Rheonix Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company